...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment.

,,,fouremm,,,,being the eternal optimist that I really am,,,, :o) ,,,,,perhaps we have a bidding war between the BPs listed in these presentations and trials!!,,,,that would of course be out a ways,,,,5,,maybe 10,,or even 20 years out,,,,,you know ,,nothing can get done in a life time with this management team. We actually do have impressive company in partnership.

However,,,our nursery with these other molecules seems to be stagnated,,,,,but it does offer a full career to our team,,,,,,,20 years to get 1 molecule to the forefront,,,hummmm,,,,,cant imagine what timing can be interpolated on the others!!!,,,,,,our business model is not what I would think a progressive management team would undertake. On the outside it looks like greed is the deciding factor and not humanitarian process. jmo

Share
New Message
Please login to post a reply